{"id":3954,"date":"2022-03-25T08:16:00","date_gmt":"2022-03-25T13:16:00","guid":{"rendered":"https:\/\/www.citiusminds.com\/blog\/?p=3954"},"modified":"2022-05-14T03:10:54","modified_gmt":"2022-05-14T08:10:54","slug":"potential-cancer-therapy-to-boost-immune-response","status":"publish","type":"post","link":"https:\/\/www.citiusminds.com\/blog\/potential-cancer-therapy-to-boost-immune-response\/","title":{"rendered":"Potential Cancer Therapy to Boost Immune Response"},"content":{"rendered":"\n<p>Harnessing Immune cells to combat cancer has been quite impactful for researchers in the recent past. However, according to a study by Cedars-Sinai Cancer investigators, a new approach against cancer shows prospects to transform the chemotherapy drug gemcitabine to activate immune cells to fight cancer. The scientific journal <a href=\"https:\/\/www.nature.com\/articles\/s41467-020-19970-9\"><em>Nature Communications<\/em><\/a> published the findings studied in human and mouse cancer cells.<\/p>\n\n\n\n<p>The researchers and scientists team discovered that gemcitabine converted from a non-immunogenic to an immunogenic drug, which triggered the immune cell response in the mice when they added nonsteroidal anti-inflammatory celecoxib (Celebrex) to gemcitabine chemotherapy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2021\/08\/jc-gellidon-xX0NVbJy8a8-unsplash.jpg\"><img decoding=\"async\" src=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2021\/08\/jc-gellidon-xX0NVbJy8a8-unsplash.jpg\" alt=\"\" class=\"wp-image-3936\"\/><\/a><\/figure>\n\n\n\n<p>This discovery might increase the percentage of patients responding to cancer immunotherapy since currently, only <a href=\"https:\/\/www.hopkinsmedicine.org\/inhealth\/about-us\/immunotherapy-precision-medicine-action-policy-brief.html\" target=\"_blank\" rel=\"noreferrer noopener\">15-25%<\/a> of patients taking immunotherapy drugs respond to them successfully. Over many years, immunotherapy drugs have been added to chemotherapy regimens to make patients&#8217; immune cells attack cancer; the success rate is low, though.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2021\/08\/testalize-me-0jE8ynV4mis-unsplash.jpg\"><img decoding=\"async\" src=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2021\/08\/testalize-me-0jE8ynV4mis-unsplash.jpg\" alt=\"\" class=\"wp-image-3933\"\/><\/a><\/figure>\n\n\n\n<p>In this study, investigators from Taipei Medical University in Taiwan and Cedars-Sinai, Baylor College of Medicine in Houston discovered that gemcitabine also initiates an inhibitory or brake signal that stops the dendritic cells from activating cancer-killing T cells while releasing a &#8220;go&#8221; signal. However, if the brake is on, the T cells cannot go anywhere. Therefore, balancing the &#8220;go&#8221; and &#8220;brake&#8221; signals is necessary to prompt an effective immune response. The solution to maintaining this balance is the drug celecoxib that removes the brake signal to let the &#8220;go&#8221; signal remain. As a result, both T-cell and dendritic cells could perform immunogenic responses when Gemcitabine was converted into an immunogenic drug.<\/p>\n\n\n\n<p>Studies concluded that immune response would perform even better with an immunotherapy drug added to a gemcitabine and celecoxib treatment regimen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Harnessing Immune cells to combat cancer has been quite impactful for researchers in the recent past. However, according to a study by Cedars-Sinai Cancer investigators, a new approach against cancer shows prospects to transform the chemotherapy drug gemcitabine to activate immune cells to fight cancer. The scientific journal Nature Communications published the findings studied in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3958,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[571,369,597,511],"class_list":["post-3954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-from-the-greatest","tag-ai","tag-cells","tag-rna","tag-treatment"],"_links":{"self":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts\/3954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/comments?post=3954"}],"version-history":[{"count":0,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts\/3954\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/media\/3958"}],"wp:attachment":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/media?parent=3954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/categories?post=3954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/tags?post=3954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}